The preclinical studies on the Razi Cov Pars vaccine have been published in the Frontiers in Immunology as one of the world’s leading journals of immunology.

Ranked first in the world for citing immunology, the journal is ranked Q1 and published as open access, in which the article of Razi Cov Pars was published with an impact factor of 7.6.

The article, entitled “safety and efficacy of combined intramuscular/intranasal Razi-Cov Pars vaccine candidate against SARS-CoV-2: A preclinical study in several animal models”, is compiled by Seyed Reza Banihashem, Ali Es’haghi, Mohammad H. Fallah Mehrabadi.